@article{fdi:010014908,
  title = {{E}valuation of different {V}3 peptides in an enzyme immunoassay for specific {HIV} type 1 group 0 antibody detection},
  author = {{O}ndoa, {P}. and {W}illems, {B}. and {F}ransen, {K}. and {N}kengasong, {J}. and {J}anssens, {W}. and {H}eyndrickx, {L}. and {Z}ekeng, {L}. and {N}dumbe, {P}. and {S}imon, {F}. and {S}aragosti, {S}. and {G}ürtler, {L}. and {P}eeters, {M}artine and {K}orber, {B}. and {G}oudsmit, {J}. and {V}an der {G}roen, {G}.},
  editor = {},
  language = {{ENG}},
  abstract = {{S}trategies to discriminate group {O} from group {M} infections need to be improved. {W}e have developed and evaluated an {HIV}-1 group {O} {V}3 peptide-based enzyme immunoassay ({PEIA}) for specific {HIV}-1 group {O} antibody detection among {HIV}-1-infected patients. {S}ynthetic peptides, derived from the amino acid sequences of the {V}3 loop of 15 different group {O} strains and 7 group {O} consensus sequences, were evaluated in a {PEIA} against a panel of genetically confirmed group {O} (n=33), group {M} (n=90), and {HIV}-1 antibody-negative sera (n=17). {T}he best-performing {PEIA}(s) were then used to screen 134 sera of {E}uropean and 336 sera of {C}ameroonian origin for the presence of anti-{HIV}-1 group {O} antibodies. {T}he reactivity of reference ("gold standard") sera to individual peptides in the {PEIA} resulted in the selection of five different peptides with sensitivities (sens), specificities (spec), and test efficiencies ({TE}s) in the range of 90 to 100%. {I}mprovement of the {PEIA} was obtained with simultaneous reactivity of at least two different peptides in separate wells of an {ELISA} plate, together with stringent criteria for positivity. {W}e were able to select seven peptide combinations each with a sens, spec, and {TE} of 96.9, 100, and 99.2%, respectively. {N}one of the 134 {E}uropean and 4 (1.2%) of the 336 {C}ameroonian samples sera were group {O} positive in the optimized {HIV}-1 group {O} {PEIA} ; this was confirmed by the repeated presence of reactives, in agreement with the present knowledge of group {O} infection distribution. {F}inally, we were able to develop a strategy with a higher {TE} (99.2%) than the previously used {ANT}-70 (98.5%) and {ANT}-70/{MVP}5180 (95.7%). {O}ur results show that optimal specificity rather than optimal sensitivity makes the {V}3 {PEIA} a sufficiently accurate epidemiological tool to be useful in estimating specifically group {O} infection among {HIV}-1-infected patients. ({R}{\'e}sum{\'e} d'auteur)},
  keywords = {{SIDA} ; {VIRUS} ; {EPIDEMIOLOGIE} ; {DIAGNOSTIC} ; {ANTICORPS} ; {TEST} ; {IMMUNOLOGIE} ; {VIH}-1 {GROUPE} {O}},
  booktitle = {},
  journal = {{AIDS} {R}esearch and {H}uman {R}etroviruses},
  volume = {14},
  numero = {11},
  pages = {963--972},
  ISSN = {0889-2229},
  year = {1998},
  DOI = {10.1089/aid.1998.14.963},
  URL = {https://www.documentation.ird.fr/hor/fdi:010014908},
}